1.
Fedorow H,
Tribl F,
Halliday G,
et al.
Neuromelanin in human dopamine neurons; comparison with peripheral melanins and relevance to Parkinson’s disease.
ProgNeurobiol 2005;75:109-24.
2.
Zecca L,
Tampellini D,
Gerlach M,
et al.
Substantia nigra neuromelanin: structure,
synthesis,
and molecular behavior.
Mol Pathol 2001;54:414-8.
3.
Damier P,
Hirsch EC,
Agid Y,
et al.
The substantia nigra of the human brain.
II.Patterns of loss of dopamine-containing neurons in Parkinson’s disease.
Brain1999;122:1437-48.
4.
Fearnley JM,
Lees AJ.
Aging and Parkinson’s disease: substantia nigra regional selectivity.
Brain 1991;114:2283-301.
5.
Halliday GM,
McRitchie DA,
Cartwright HR,
et al.
Midbrain neuropathology in idiopathic Parkinson’s disease and diffuse Lewy body disease.
J Clin Neurosci 1996;3:52-60.
6.
Förstl H,
Burns A,
Luthert P,
et al.
Clinical and neuropathological correlates of depression in Alzheimer’s disease.
Psychol Med 1992;22:877-84.
7.
Sasaki M,
Shibata E,
Tohyama K,
et al.
Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson’s disease.
NeuroReport 2006;17:1215-18.
8.
Mann DM,
Yates PO.
Possible role of neuromelanin in the pathogenesis of Parkinson’s disease.
Mech Ageing Dev 1983;21:193-203.
9.
Schwarz ST,
Rittman T,
Gontu V,
et al.
T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson’s disease.
Mov Disord 2011;26:1633-8.
10.
Kashihara K,
Shinya T,
Higaki F.
Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson’s disease.
J Clin Neuroscience 2011;18:1093-96.
11.
Wieland DM,
Brown LE,
Rogers WL,
et al.
Myocardial imaging with a radioiodinated norepinephrine storage analog.
J Nucl Med 1981;22:22-31.
12.
Druschky A,
Hilz MJ,
Platsch G,
et al.
Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG-SPECT.
J Neurol Sci 2000;175:3-12.
13.
Spiegel J,
Hellwig D,
Farmakis G et al.
Myocardial sympathetic degeneration correlates with clinical phenotype of Parkinson’s disease.
Mov Disord 2007;22:1004-8.
14.
Pahwa R,
Lyons KE.
Early diagnosis of Parkinson’s disease: recommendations from diagnostic clinical guidelines.
Am J Manag Care 2010;16(Suppl):S94-99.
15.
Hoehn MM,
Yahr MD.
Parkinsonism: onset,
progression and mortality.
Neurology 1967;17:427-42.
16.
Imai Y,
Hasegawa K.
The revised Hasegawa’s dementia scale (HDS-R) – evaluation of its usefulness as a screening test for dementia.
J Hong Kong Coll Psychiatr 1994;4: 20–24.
17.
Tanabe Y,
Harada H,
Sugihara S,
Ogawa T,
Inoue Y. 123I-metaiodobenzylguanidine myocardial scintigraphy in panic disorder.
J Nucl Med 2004; 45:1305-1308.
18.
Tanaka M,
Aihara Y,
Ikeda S,
Aihara Y.
Neuromelanin-related contrast in the
substantia nigra semiquantitatively evaluated by magnetic resonance imaging at 3T:comparison between normal aging and Parkinson disease.
Clin Neurol 2011;51:14-20.
19.
Braak H,
Del Tredici K,
Rub U,
de Vos RA,
Jansen Steur EN,
Braak E.
Staging of brain pathology related to sporadic Parkinson’s disease.
Neurobiol Aging 2003;24:197-211.
20.
Halliday GM,
Ophof A,
Broe M,
et al.
α-Synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson’s disease.
Brain 2005;128:2654-64.
21.
Isaias IU,
Marotta G,
Pezzoli G,
et al.
Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease.
BMC Neurol 2011;11:88.
22.
Rommelfanger KS,
Weinshenker D.
Norepinephrine: the redheaded stepchild of Parkinson’s disease.
Biochem Pharmacol 2007;74:177-90.
23.
Weinshenker D.
Functional consequences of locus coeruleus degeneration in Alzheimer’s disease.
Curr Alzheimer Res 2008;5:342-45.
24.
Haneka MT,
Nadrigny F,
Regen T,
et al.
Locus ceruleus controls Alzheimer’s disease pathology by modulating microglial functions through norepinephrine.
Proc Natl Acad Sci USA 2010;107:6058-63.
25.
Busch C,
Bohl J,
Ohm TG.
Spatial,
temporal and numeric analysis of Alzheimer changes in the nucleus ceruleus.
Neurobiol Aging.
1997;18:401-6.
26.
Okada Y,
Ito Y,
Aida J,
et al.
Lewy bodies in the sinoatrial nodal ganglion: clinicopathological studies.
Pathol Int 2004;54:682-87.
27.
Orimo S,
Takahashi A,
Uchihara T,
et al.
Degeneration of cardiac sympathetic nerve begins in the early disease process of Parkinson’s disease.
Brain Pathol 2007;17:24-30.
28.
Rascol O,
Schelosky L.
123I-metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders.
Mov Disord 2009;24(Suppl 2):S732-41.
29.
Watanabe M,
Takeda T,
Nakamagoe K,
et al.
Sequential imaging analysis using MIBG scintigraphy revealed progressive degeneration of cardiac sympathetic nerve in Parkinson’s disease.
Eur J Neurol 2011;18:1010-13.